The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

References

Page 1

	Year	Citations
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou, Circulation	2013	1.3K
Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes Hiddo J.L. Heerspink, Dick de Zeeuw, Li Wie, Diabetes Obesity and Metabolism	2013	801
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial Dick de Zeeuw, Rajiv Agarwal, Michael Amdahl, The Lancet Renal FunctionVital StudyDiabetesPharmacologyType 2	2010	686
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control Donald E. Kohan, Paola Fioretto, Weihua Tang, Kidney International ObesityMetabolic SyndromeHypertensionMean Serum CreatinineRenal Function	2013	633
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial Anthony Barnett, Ambrish Mithal, Jenny Manassie, The Lancet Diabetes & Endocrinology Diabetes ManagementInsulin ManagementDiabetesChronic Kidney DiseasePharmacology	2014	567
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease J.‐F. Yale, George L. Bakris, Bertrand Cariou, Diabetes Obesity and Metabolism	2013	480
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice Volker Vallon, Maria Gerasimova, Michael Rose, American Journal of Physiology-Renal Physiology	2013	470
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou, Cardiovascular Diabetology	2014	458
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial Michael Roden, Jianping Weng, Jens Eilbracht, The Lancet Diabetes & Endocrinology Diabetes ManagementCardiovascular DiseaseMedicineDiabetesActive Comparator	2013	438
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Diabetes Care	2014	383

Page 1